GlassScriptPhysician profile
Rajnikant B Patel
NPI 1417957242
$1,923.57
in general payments reported to CMS, 2019-2025
23 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $277 · 2021: $716 · 2022: $153 · 2023: $285 · 2024: $111 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $244.77 | 2019-2025 | Rexulti |
| Allergan, INC. | $228.35 | 2019-2020 | |
| Eisai INC. | $207.29 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.94 | 2020-2022 | |
| Abbvie INC. | $131.25 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $98.88 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $95.56 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.63 | 2022-2024 | Caplyta |
| Merck Sharp & Dohme LLC | $91.83 | 2021 | |
| Sunovion Pharmaceuticals INC. | $91.70 | 2020-2021 | |
| Neos Therapeutics, LP | $89.59 | 2023 | Adzenys Xr-Odt |
| Lundbeck LLC | $81.89 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $70.45 | 2021 | |
| Axsome Therapeutics, INC. | $38.68 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $27.55 | 2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $24.68 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $20.52 | 2025 | Cobenfy |
| Neuronetics, INC. | $19.70 | 2019 | |
| Adlon Therapeutics L.P. | $19.06 | 2020 | |
| Shire North American Group INC | $18.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.76 | 2021 | |
| Almatica Pharma LLC | $13.55 | 2023 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajnikant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.